CoChat

Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: The EXAMINE trial

Open access
Heller, Simon R., Bergenstal, Richard M., White, William B., Kupfer, Stuart, Bakris, George L., Cushman, William C., Mehta, Cyrus R., Nissen, Steven E., Wilson, Craig A., Zannad, Faiez, Liu, Yuyin, Gourlie, Noah M., Cannon, Christopher P., for the EXAMINE Investigators · 2017 · Diabetes, Obesity and Metabolism
Cited by 58

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Aims: To investigate relationships between glycated haemoglobin ( HbA1c ) and reported hypoglycaemia and risk of major adverse cardiovascular events ( MACE ). Methods: The EXAMINE trial randomized 5380 patients with type 2 diabetes ( T2DM ) and a recent acute coronary syndrome ( ACS ) event, in 49 countries, to double‐blind treatment with alogliptin or placebo in addition to standard of care. We used Cox proportional hazards models to analyse relationships among MACE , HbA1c levels and hypoglycaemic events. Results: Patients randomized to alogliptin achieved lower HbA1c levels than the placebo group in all baseline HbA1c categories without differences in hypoglycaemia rates. No systematic change was found in MACE rates according to baseline HbA1c ( P interaction = 0.971) or HbA1c category at 1 month. Patients in the combined treatment groups (n = 5380) who experienced serious hypoglycaemia (n = 34) had higher MACE rates than those who did not (35.3% vs 11.4%, adjusted hazard ratio [ HR ] 2.42, 95% confidence interval [ CI ] 1.27–4.60; P = .007), although the association was less strong when analysing only events after the hypoglycaemic event (adjusted HR 1.60, 95% CI 0.80, 3.20). Conclusions: There were no relationships between baseline HbA1c levels or HbA1c levels after 1 month of treatment and the risk of MACE . Alogliptin improved glycaemic control without increasing hypoglycaemia. Reported events of hypoglycaemia and serious hypoglycaemia were associated with MACE . These data underscore the safety of alogliptin in improving glycaemic control in T2DM post‐ ACS . Further study of hypoglycaemia as an independent risk factor for MACE in patients with T2DM and coronary disease is needed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.12871

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 58

Metadata

Authors
Heller, S. R., Bergenstal, R. M., White, W. B., Kupfer, S., Bakris, G. L., Cushman, W. C., Mehta, C. R., Nissen, S. E., Wilson, C. A., Zannad, F., Liu, Y., Gourlie, N. M., Cannon, C. P., & for the EXAMINE Investigators
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2017-02-27
Volume
19
Issue
5
Pages
664-671
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2569266935
Cited by
58
References
9
FWCI
6.12
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: The EXAMINE trial. https://app.cochat.ai/papers/10.1111/dom.12871
The paper
Heller, S. R., Bergenstal, R. M., White, W. B., Kupfer, S., Bakris, G. L., Cushman, W. C., Mehta, C. R., Nissen, S. E., Wilson, C. A., Zannad, F., Liu, Y., Gourlie, N. M., Cannon, C. P., & for the EXAMINE Investigators. (2017). Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: The EXAMINE trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12871

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.